SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes (SCOPE)
Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE Trial
研究概览
地位
详细说明
Randomization and blinding: Eligible participants will be randomly assigned in a 1:1 ratio to either the dapagliflozin group or the standard care control group using a centralized, computer-generated randomization sequence. This is an open-label trial; however, all outcome assessments will be performed by core laboratories blinded to treatment allocation. Imaging analyses for plaque volume, hemodynamic parameters, and perivascular adipose tissue metrics will be conducted by investigators masked to group assignment.
Intervention: Participants in the intervention group receive dapagliflozin 10 mg once daily in addition to their standard diabetes and cardiovascular care. Participants in the control group receive standard glycemic management according to current clinical guidelines, with the exclusion of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors. The total study duration is 18 months.
Study procedures: At baseline, participants will undergo coronary computed tomography angiography (CCTA) using a standardized protocol. Blood samples will be collected for lipid panels and inflammatory markers. Quality of life will be assessed using the Seattle Angina Questionnaire (SAQ-7). Follow-up visits are scheduled at 6, 12, and 18 months. At each visit, adverse events, concomitant medications, and medication adherence will be recorded. The 18-month visit will include a repeat CCTA and blood sampling.
Imaging core laboratory: All CCTA images will be transferred to an independent core laboratory for quantitative analysis. Plaque volume and composition will be assessed using semi-automated software. CT-derived fractional flow reserve (CT-FFR) will be computed using a dedicated algorithm. Wall shear stress (WSS) will be derived from computational fluid dynamics. Perivascular adipose tissue parameters, including fat attenuation index (FAI) and fat volume, will be measured using a validated software tool.
Data and safety monitoring: An independent Data and Safety Monitoring Board (DSMB) will review unblinded safety data every 6 months. The DSMB will monitor for serious adverse events, including volume depletion, genital infections, hypoglycemia, diabetic ketoacidosis, and acute kidney injury. Protocol-defined stopping rules include a significant increase in any of these events in the intervention arm.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Junjie Yang, MD
- 电话号码:010-55499209
- 邮箱:fearlessyang@126.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- 招聘中
- The First Medical Center of Chinese PLA General Hospital
-
接触:
- Junjie Yang
- 电话号码:010-55499345
- 邮箱:fearlessyang@126.com
-
Beijing、Beijing Municipality、中国
- 招聘中
- The Sixth Medical Center of Chinese PLA General Hospital
-
接触:
- Junjie Yang, MD
- 电话号码:010-55499209
- 邮箱:fearlessyang@126.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age between 18 and 75 years.
- Confirmed diagnosis of type 2 diabetes mellitus with SCORE2-Diabetes risk score >10%.
- Stable angina pectoris.
- Coronary CT angiography (CCTA) demonstrating 50%-90% stenosis in at least one coronary vessel with diameter ≥2.5 mm.
- CT-derived fractional flow reserve (CT-FFR) >0.8 in the target vessel.
- Stable standard therapy for diabetes and cardiovascular disease, with no changes in SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors within the past 4 weeks.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) with stenting, prosthetic valve replacement, or permanent pacemaker implantation.
- New York Heart Association (NYHA) functional class III or IV heart failure. Acute myocardial infarction within the previous 30 days.
- Known allergy to iodinated contrast media or other contraindications to CCTA. Severe arrhythmia or coronary artery calcium (CAC) score >400.
- Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m². History of serious adverse reactions to SGLT2 inhibitors.
- Pregnancy, lactation, or planned pregnancy during the study period. Severe liver dysfunction (Child-Pugh class C).
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SGLT2 Inhibitor Group
Participants with type 2 diabetes and coronary atherosclerosis receive dapagliflozin 10 mg orally once daily in addition to standard diabetes care for 18 months.
|
Dapagliflozin 10 mg tablet administered orally once daily for 18 months, in addition to standard diabetes and cardiovascular care, to evaluate its effects on coronary atherosclerosis progression mediated by perivascular adipose tissue in patients with type 2 diabetes.
Standard glycemic and cardiovascular management according to clinical guidelines, excluding SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors, for 18 months.
|
|
有源比较器:Control Group
Participants receive standard diabetes care without SGLT2 inhibitors for 18 months.
|
Standard glycemic and cardiovascular management according to clinical guidelines, excluding SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors, for 18 months.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression of Coronary Plaque Volume and Proportion from Baseline to the 18-Month Follow-Up
大体时间:Baseline to 18 months
|
Progression of total plaque volume (TPV) (mm³)from baseline or appearance of new plaques, assessed by coronary CT angiography (CCTA).
Includes changes in plaque components (e.g., necrotic core, fibrous cap, calcification)(mm³).
|
Baseline to 18 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in the Coronary Perivascular Fat Radiomics Score (FRS) from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in the coronary perivascular fat radiomics score (FRS), measured in "points", where a higher score indicates a higher inflammatory activity state and a stronger correlation with the risk of major adverse cardiovascular events.
|
Baseline to 18 months
|
|
Change in CT-derived fractional flow reserve (CT-FFR) from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in CT-derived fractional flow reserve (CT-FFR), expressed as a pure number between 0 and 1 (no units), where a higher value indicates a lower likelihood of ischemia.
|
Baseline to 18 months
|
|
Change in Fat Attenuation Index (FAI)from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in fat attenuation index (FAI)(HU) .FAI is defined as the mean attenuation value of pericoronary adipose tissue observed on CT scan, ranging from approximately -190 to -30 HU.
Higher values indicating increased perivascular adipose tissue inflammation and coronary vulnerability, and lower values suggesting a more stable, anti-inflammatory vascular state.
|
Baseline to 18 months
|
|
Change in the Degree of Coronary Artery Stenosis from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in the degree of coronary artery stenosis, expressed as CAD-RADS category or quantitatively measured percent stenosis.
CAD-RADS grades range from 0 to 5, with higher grades indicating greater stenosis severity.
Quantitatively measured percent stenosis ranges from 0% to 100%, with higher percentages indicating greater stenosis severity.
|
Baseline to 18 months
|
|
Change in C-reactive protein (CRP) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in C-reactive protein (CRP).
Reference range: 0-0.8 mg/L; Unit: mg/dL.
|
Baseline to 18 months
|
|
Change in Quality of Life Score as Assessed by the Seattle Angina Questionnaire (SAQ-7) from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in quality of life score measured by the Seattle Angina Questionnaire (SAQ-7).
The total score ranges from 0 to 100, with higher scores indicating better quality of life and better angina control.
|
Baseline to 18 months
|
|
Occurrence of Major Adverse Cardiovascular Events (MACE) from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Occurrence of major adverse cardiovascular events (MACE), including but not limited to cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, from baseline to the 18-month follow-up.
|
Baseline to 18 months
|
|
Change in Self-Rating Anxiety Scale(SAS) Score from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in the Self-Rating Anxiety Scale (SAS) score. The SAS is a 20-item self-reported scale with 4-point scoring, designed to assess the subjective experience of anxiety in patients. Total scores range from 0 to 60, with higher scores indicating greater anxiety severity. The scores are interpreted as follows: A (0-8): no anxiety disorder B (9-21): occasional anxiety C (22-32): mild anxiety disorder D (33-44): moderate anxiety disorder E (45-60): severe anxiety disorder |
Baseline to 18 months
|
|
Change in Hamilton Anxiety Scale (HAMA) Score from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in the Hamilton Anxiety Scale (HAMA) score. HAMA is a clinician-rated scale consisting of 14 items, each scored from 0 to 4, where: 0 = asymptomatic
Total scores range from 0 to 56, with higher scores indicating more severe anxiety. The score is interpreted as follows: <7: no anxiety symptoms 7-13: possible anxiety 14-20: mild anxiety 21-28: marked anxiety 29: severe anxiety |
Baseline to 18 months
|
|
Change in wall shear stress (WSS) from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in wall shear stress (WSS)(Pa).Both excessively high and abnormally low WSS are pathological: high WSS promotes plaque destabilization and rupture, while low WSS accelerates atherogenesis and plaque growth.
|
Baseline to 18 months
|
|
Change in Pericoronary Adipose Tissue Volume from Baseline to 18 Months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in Pericoronary Adipose Tissue Volume (mm³).Larger volume indicates higher inflammatory activity or greater disease burden, whereas smaller volume indicates the opposite.
|
Baseline to 18 months
|
|
Change in lipoprotein(a) (Lp(a)) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in lipoprotein(a) (Lp(a)).
Reference range: <30 mg/dL; Unit: mg/dL.
|
Baseline to 18 months
|
|
Change in low-density lipoprotein cholesterol (LDL-C) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in low-density lipoprotein cholesterol (LDL-C).
Reference range: 0-3.4;
Unit: mmol/L.
|
Baseline to 18 months
|
|
Change in high-density lipoprotein cholesterol (HDL-C) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in high-density lipoprotein cholesterol (HDL-C).
Reference range: 1-1.6 ; Unit: mmol/L.
|
Baseline to 18 months
|
|
Change in triglycerides (TG) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in triglycerides (TG).
Reference range: 0.4-1.7;
Unit: mmol/L.
|
Baseline to 18 months
|
|
Change in total cholesterol (TC) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in total cholesterol (TC).
Reference range: 3.1-5.7;
Unit: mmol/L.
|
Baseline to 18 months
|
|
Change in interleukin-6 (IL-6) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in interleukin-6 (IL-6).
Reference range: 0-5.9 pg/mL; Unit: pg/mL.
|
Baseline to 18 months
|
|
Change in tumor necrosis factor-alpha (TNF-α) from baseline to 18 months
大体时间:Baseline to 18 months
|
Change from baseline to the 18-month follow-up in tumor necrosis factor-alpha (TNF-α).
Reference range: <20; Unit: ng/L.
|
Baseline to 18 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- S2025-052-01
- 82470342 (其他赠款/资助编号:National Natural Science Foundation of China)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.